Pharmaceutical Technology

FEBRUARY 3, 2023

Only a few weeks into the new year, the prospect of getting a successful advanced HIV vaccine shrank after the discontinuation of yet another late-stage trial. On January 18, Janssen, a Johnson & Johnson (J&J) subsidiary, stated that its vaccine was not effective in preventing HIV infections.

Vaccination 293

Vaccination Vaccine Antibody Trials 293

Pharmaceutical Technology

MAY 29, 2023

Novavax has received positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for full marketing authorisation (MA) of its Covid vaccine, Nuvaxovid (NVX-CoV2373) , in the European Union (EU). The safety and efficacy of Nuvaxovid was evaluated as a primary series.

Vaccination 130

Vaccination Vaccine Protein Immune Response 130

The Pharma Data

AUGUST 16, 2021

The study assessed cynomolgus macaques vaccinated with 12µg of either the first or second-generation vaccine candidate. During challenge with the original SARS-CoV-2 virus, animals vaccinated with CV2CoV were found to be better protected based on highly effective clearance of the virus in the lungs and nasal passages.

Immune Response 52

Immune Response Vaccination Vaccine Antibody 52

NY Times

MAY 11, 2022

Antibody levels rose in the children who received it, suggesting the vaccine protects against infection. But the data were gathered before the arrival of Omicron.

Immune Response 62

Immune Response Vaccination Vaccine Antibody 62

Drug Discovery World

AUGUST 3, 2023

Bimervax from HIPRA Human Health has been authorised in the UK after meeting the Medicines & Healthcare products Regulatory Agency’s (MHRA) required safety, quality and effectiveness standards. It becomes the ninth Covid-19 vaccine to be authorised by the UK’s independent medicines regulator.

Vaccination 52

Vaccination Vaccine Immune Response Medicine 52

XTalks

MAY 17, 2024

Every year on May 18th, the global community commemorates World AIDS Vaccine Day, also known as HIV Vaccine Awareness Day. Led by the National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID), World AIDS Vaccine Day emphasizes the importance of awareness and education in the fight against HIV/AIDS.

Vaccination 52

Vaccination Vaccine Research Immune Response 52

Pharmaceutical Technology

NOVEMBER 11, 2022

The European Commission (EC) has granted approval for Sanofi and GSK ’s monovalent, recombinant-protein-based, adjuvanted Covid-19 vaccine, VidPrevtyn Beta, as a booster in adults aged 18 years and above. It is indicated as a booster in people of this age group who were earlier inoculated with a Covid-19 vaccine.

Vaccination 246

Vaccination Vaccine Immune Response Protein 246

The Pharma Data

JULY 11, 2021

Phase 3 study met primary and secondary endpoints demonstrating MenQuadfi ® induced superior immune responses to serogroup C compared to a standard-of-care vaccine in healthy toddlers MenQuadfi is the first and only quadrivalent ACWY vaccine to demonstrate superior immune response against serogroup C in toddlers.

Immune Response 52

Immune Response Vaccination Vaccine Licensing 52

Medical Xpress

DECEMBER 5, 2022

Research by RCSI University of Medicine and Health Sciences has provided new insights into the mechanism behind how our circadian 24-hour body clock influences our immune response to vaccines, depending on the time of day.

Vaccination 75

Vaccination Vaccine Immune Response Research 75

XTalks

FEBRUARY 19, 2024

Moderna has been testing an experimental mRNA vaccine aimed at combating the human cytomegalovirus (CMV), which poses significant health risks to newborns and immunocompromised patients. The team used the data and patient samples from a gB/MF59 Phase II trial in adolescent girls as a benchmark to assess the new mRNA-based vaccine.

Vaccination 59

Vaccination Vaccine Trials Clinical Trials 59

Pharmaceutical Technology

APRIL 10, 2023

It will also be used for the treatment of people who are not likely to have an adequate immune response to Covid-19 vaccination or for people who are not recommended for Covid-19 vaccination. Dr Noor Hisham was quoted as saying: “The use of Evusheld was based on clinical guidelines issued by the health ministry.”

Immune Response 264

Immune Response Antibody Vaccination Vaccine 264

Pharmaceutical Technology

MARCH 31, 2023

The European Medicines Agency (EMA) has recommended HIPRA’s Covid-19 vaccine , Bimervax, as a Covid-19 booster. Available to people ages 16 years and above who have been vaccinated with a Covid-19 mRNA vaccine, EMA’s Human Medicines Committee concluded the vaccine is ready for marketing authorization in the EU, on 30 March.

Vaccination 277

Vaccination Vaccine Immune Response Antibody 277

Scienmag

NOVEMBER 16, 2021

Despite great progress with SARS-CoV-2 vaccines, there is still a need to accelerate vaccination in low- and middle-income countries and a need for more effective vaccine strategies in older adults, who tend to have weaker immune responses to vaccination.

Protein 84

Protein Vaccination Vaccine Immune Response 84

Medical Xpress

DECEMBER 1, 2022

In 2021, a group of scientists led by researchers at the University of North Carolina at Chapel Hill, Weill Cornell Medicine and NewYork-Presbyterian reported that the Moderna mRNA vaccine and a protein-based vaccine candidate containing an adjuvant, a substance that enhances immune responses, elicited durable neutralizing antibody responses to SARS-CoV-2 (..)

Vaccination 75

Vaccination Vaccine Immune Response Containment 75

Scienmag

APRIL 19, 2021

A study of immune cells circulating in the blood hints the gut’s immune response to COVID-19 infection may not provide sufficient whole-body immunity from the virus Our guts may not provide long-lasting systemic immunity from COVID-19, which is where immune cells circulate through the body to provide protection to other organs, finds a new study (..)

Immune Response 74

Immune Response Allergies Vaccination Vaccine 74

The Pharma Data

OCTOBER 29, 2021

Data published in PLOS Medicine demonstrated that the Johnson & Johnson (the Company) Ebola vaccine authority, Zabdeno ® (Ad26.ZEBOV) ZEBOV) and Mvabea ® (MVA-BN-Filo), was well permitted and convinced a robust vulnerable response in both healthy grown-ups and grown-ups living with HIV.

Immune Response 40

Immune Response Medicine Vaccination Vaccine 40

Scienmag

SEPTEMBER 21, 2020

September 21, 2020–(BRONX, NY)–The first study comparing the immune responses of adults and children with COVID-19 has detected key differences that may contribute to understanding why children usually have milder disease than adults. The study was published today in Science […].

Immune Response 48

Immune Response Vaccination Vaccine Development 48

Scienmag

JANUARY 22, 2021

Results suggest lasting immunity after infection In a promising result for the success of vaccines against COVID-19, rhesus macaque monkeys infected with the human coronavirus SARS-CoV-2 developed protective immune responses that might be reproduced with a vaccine.

Immune Response 40

Immune Response Development Vaccination Vaccine 40

pharmaphorum

JANUARY 15, 2021

J&J has announced early trial results that suggest its single-shot coronavirus vaccine provides a sustained response against the virus ahead of a phase 3 trial readout due later this month. Both of these vaccines require two doses, as does the most recently approved shot from Moderna, which is due to arrive in the UK in the spring.

Vaccination 114

Vaccination Vaccine Immune Response Antibody 114

Scienmag

MARCH 25, 2021

The largest study of its kind to date also found benefit for lactating women BOSTON – In the largest study of its kind to date, researchers at Massachusetts General Hospital, Brigham and Women’s Hospital and the Ragon Institute of MGH, MIT and Harvard have found the new mRNA COVID-19 vaccines to be highly effective in […].

Immune Response 69

Immune Response Vaccination Vaccine Antibody 69

Scienmag

MAY 20, 2021

The findings provide direction for future vaccines or therapies that may offer broader protection against variants LA JOLLA, CA–Fast-spreading variants of the COVID-19-causing coronavirus, SARS-CoV-2, carry mutations that enable the virus to escape some of the immune response created naturally or by vaccination.

Immune Response 40

Immune Response Scientist Vaccination Vaccine 40

pharmaphorum

OCTOBER 5, 2022

million grant by the US government to develop an intranasal vaccine for gonorrhoea, a sexually-transmitted infection that is on the rise around the world. million in National Institutes of Health (NIH) funding to further develop a prophylactic vaccine based on its proprietary outer membrane vesicles (OMV) platform technology.

Vaccination 98

Vaccination Vaccine Immune Response Bacterium 98

Scienmag

JUNE 3, 2021

Strong immune responses to unchanging, conserved parts of the 2009 H1N1 pandemic flu virus suggest strategies for effective universal vaccines Credit: Guthmiller et al.

Immune Response 98

Immune Response Vaccination Vaccine Development 98

Pfizer

JULY 19, 2022

Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.1 1 Adapted Bivalent Vaccine Candidate. Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.1 1 Adapted Bivalent Vaccine Candidate. 1 as compared to the companies’ current COVID-19 vaccine.

Vaccination 100

Vaccination Vaccine Medicine Clinical Trials 100

pharmaphorum

JULY 18, 2022

MBA, managing director at CanSino Biologics Europe, tells us about Convidecia, a single dose SARS-CoV-2 vaccine offered as an injectable and inhalant that allows ease of storage, an alternative option for individuals with needle phobias, and robust elongated CD4 and CD8 cellular response. Morgon, PharmD, LL.M, How it works.

Vaccination 136

Vaccination Vaccine Development Immune Response 136

Scienmag

SEPTEMBER 30, 2021

In a study published today in the American Journal of Transplantation, Johns Hopkins Medicine researchers say that children between the ages of 12 and 18 who have received solid organ transplants appear to mount a more robust immune response than their adult counterparts after a standard two-dose vaccination regimen against SARS-CoV-2, the virus that (..)

Vaccination 68

Vaccination Vaccine Immune Response Medicine 68

The Pharma Data

JULY 15, 2021

Antibody and T-cell immune responses strong and stable at eight months after immunization Demonstrated neutralizing antibody activity against the Delta variant (B.1.617.2) of Beth Israel Deaconess Medical Center suggest maturation of B-cell response without further boosting. 1.1.7), Beta (B.1.351), 1.351), Gamma (P.1),

Immune Response 52

Immune Response Medicine Vaccination Vaccine 52

BioSpace

JANUARY 14, 2021

Johnson & Johnson published interim Phase I/IIa data in the New England Journal of Medicine showing its single-dose COVID-19 vaccine candidate created an immune response that lasted at least 71 days.

Immune Response 82

Immune Response Vaccination Vaccine Medicine 82

Scienmag

MAY 26, 2021

In series of samples collected from individuals vaccinated against COVID-19, an ultrasensitive test detected low concentrations of circulating antigen; Following robust production of antibodies, viral protein declined to undetectable levels The carefully orchestrated dance between the immune system and the viral proteins that induce immunity against (..)

Immune Response 54

Immune Response Protein Vaccination Vaccine 54

Scienmag

JANUARY 26, 2022

WHAT: In adults who had previously received a full regimen of any of three COVID-19 vaccines granted Emergency Use Authorization (EUA) or approved by the Food and Drug Administration (FDA), an additional booster dose of any of these vaccines was safe and prompted an immune response, according to preliminary clinical trial results reported in The […]. (..)

Vaccination 84

Vaccination Vaccine Immune Response Trials 84

Drug Discovery World

AUGUST 17, 2023

It is believed that new Covid-19 vaccines developed by Pfizer/BioNTech, Moderna and Novavax will be effective against the fast-spreading EG.5 The new vaccine versions all target Omicron subvariant XBB.1.5, 5, though the latter does contain one particular mutation that is known to evade immunity. Focus on Omicron subvariant XBB.1.5

Vaccination 52

Vaccination Vaccine Immune Response Manufacturing 52

Scienmag

JANUARY 18, 2021

Novel tuberculosis vaccine demonstrated strong immune response in mice Credit: University of Sydney Scientists in Australia have developed a method for the rapid synthesis of safe vaccines, an approach that can be used to test vaccine strategies against novel pandemic pathogens such as SARS-CoV-2, the virus that causes COVID-19.

Vaccination 93

Vaccination Vaccine Immune Response Scientist 93

Drug Discovery World

OCTOBER 13, 2023

The scientists say the tool can help inform the development of vaccines and therapies for SARS-CoV-2 and other rapidly mutating viruses. The University has also launched a new global consortium to research and develop next-generation Covid-19 and flu vaccines, backed by £8 ($9.8) million funding from UK Research and Innovation (UKRI).

Vaccination 105

Vaccination Vaccine Immune Response Scientist 105

Scienmag

SEPTEMBER 21, 2020

Their work emphasizes how dependent the future course of the pandemic is on the nature of the adaptive immune response to this virus and on […].

Immune Response 46

Immune Response Vaccination Vaccine Research 46

pharmaphorum

NOVEMBER 25, 2022

Scientists in the US say they have developed an mRNA-based vaccine that encompasses all 20 known subtypes of influenza that could form the basis of a future universal jab. The goals of the programme are also similar to those in COVID vaccine development.

Vaccination 104

Vaccination Vaccine Research Immune Response 104

Pharmaceutical Technology

JULY 25, 2022

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended an update to the conditional marketing authorization (CMA) to include Moderna ’s 50µg booster dose of Covid-19 vaccine, Spikevax, for usage in adolescents aged 12 to 17 years.

Immune Response 147

Immune Response Vaccination Vaccine Medicine 147

Scienmag

DECEMBER 9, 2020

Phase 2 trials in 1,200 adults, young children, and infants suggest new poliovirus vaccine may have the potential to overcome outbreaks caused by a mutated polio strain linked to the oral vaccine that typically circulates in areas of low immunisation coverage, and poses one of biggest barriers to eradication.

Immune Response 75

Immune Response Vaccination Vaccine Scientist 75